Regulus Therapeutics (RGLS) Tops Q4 EPS by 2c

March 7, 2018 4:18 PM

Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

Categories

Earnings Guidance

Next Articles